And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...
Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.30404 EPS, expectations were $-0.04. Operator ...
Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety ...
Authored by Steve Keating, Managing Director of BCG, the report--"The Evolution of Pension Risk Transfer in the United States: A 50-Year Timeline (1974-2025)", serves as a reference for plan sponsors, ...
The Boston Consulting Group's Christine Barton and Mrin Nayak detailed research on the next generation of consumers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback